0000950170-24-035461.txt : 20240322 0000950170-24-035461.hdr.sgml : 20240322 20240322170333 ACCESSION NUMBER: 0000950170-24-035461 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240322 FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dorling Janet CENTRAL INDEX KEY: 0001738144 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36500 FILM NUMBER: 24776092 MAIL ADDRESS: STREET 1: C/O ACHAOGEN, INC. STREET 2: 1 TOWER PLACE, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc. CENTRAL INDEX KEY: 0001042074 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943103561 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-293-8800 MAIL ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX, INC. DATE OF NAME CHANGE: 20090721 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX INC DATE OF NAME CHANGE: 19970710 4 1 ownership.xml 4 X0508 4 2024-03-22 true 0001042074 CymaBay Therapeutics, Inc. CBAY 0001738144 Dorling Janet C/O CYMABAY THERAPEUTICS, INC. 7601 DUMBARTON CIRCLE FREMONT CA 94555 true false false false false Employee Stock Option (right to buy) 4.63 2024-03-22 4 D false 55000 D 2031-04-04 Common Stock 55000 0 D Employee Stock Option (right to buy) 2.94 2024-03-22 4 D false 67000 D 2032-01-24 Common Stock 67000 0 D Employee Stock Option (right to buy) 7.80 2024-03-22 4 D false 25000 D 2033-01-24 Common Stock 25000 0 D Employee Stock Option (right to buy) 22.85 2024-03-22 4 D false 14010 D 2034-01-23 Common Stock 14010 0 D Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. /s/ Paul Quinlan, as attorney-in-fact for Janet Dorling 2024-03-22